Westport, CT, April 16, 2020 -- Broad Spectrum Antiviral Produced by ViralClear Pharmaceuticals, Inc., a subsidiary of BioSig Technologies, Inc.IND filing with FDA expected in.

Westport, CT, April 30, 2020 -- BioSig Technologies, Inc. (Nasdaq: BSGM) today announced that an article titled, “The IMPDH inhibitor merimepodib provided in combination with.

BioSig Technologies, Inc. (Nasdaq: BSGM) today announced that an article titled, “The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro” was published by F1000 Research, an online peer-reviewed life sciences journal publishing program in biology and medicine, while it is undergoing peer review. This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, Timothy Wanninger, John T. Manning, Cheng Huang and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding author.

Mr. Schmertzler has been the Chairman of the board of directors of PTC Therapeutics, Inc. since 2004, where he was a founding institutional investor. Mr. Schmertzler is currently the independent director of Lehman Commercial Paper, Inc., the largest subsidiary of the liquidating post-bankruptcy Lehman Brothers estate.

Westport, CT, May 05, 2020 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Dennis Purcell to the Board of Directors of its.

Westport, CT, May 01, 2020 -- Clinical support staff to return to perform elective procedures at Texas Cardiac Arrhythmia Institute as of May 4, 2020Company reconfirms its.

Jerome (“Jerry”) Zeldis, M.D., Ph.D brings extensive life sciences experience gained primarily through his career at Celgene, Inc. He previously served as Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation, a publicly traded, fully integrated biopharmaceutical company, where he was employed for nearly 20 years, starting in 1997. Celgene Corporation was recently acquired by Bristol Myers-Squibb (NYSE:BMY].

Westport, CT, April 17, 2020 -- Information on the progress of our subsidiary ViralClear Pharmaceuticals and Vicromax(tm) – a broad-spectrum orally administered anti-viral.

Westport, CT, April 24, 2020 -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that it will be hosting an investor briefing to provide an.

Westport, CT, May 20, 2020 -- Funding completed in subsidiary without dilution to BioSig common stockPhase II human trials for merimepodib, a broad-spectrum oral anti-viral.

This manuscript is  authored by Natalya Bukeryeva, Emily Mantlo, Rachel Sattler, Chen Huang, Slododan Paessler of the UTMB Galveston National Laboratory and Dr.  Jerome Zeldis of ViralClear. The article is the first public disclosure of pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch.

Westport, CT, May 18, 2020 -- Phase II clinical trial expected to be conducted at multiple centers in the United States, including three Mayo Clinic sites under the leadership.

Westport, CT, April 21, 2020 -- Former senior executive at AstraZeneca and pharmaceutical industry expert to join as Independent Director The Company is developing Vicromax(tm).

The Company intends to pursue development of this agent for the treatment of COVID-19 through FDA-approved clinical trials. The product candidate already completed Phase I and three Phase II trials in other indications, and underwent extensive animal testing and human clinical experience.

Westport, CT, April 03, 2020 -- Introduction to ViralClear management and scientific teamStrategy for rapid FDA advancement of Vicromax(tm)Update on BioSig core business.

On March 31, 2020, the FDA created the Coronavirus Treatment Acceleration Program (CTAP), a special emergency program for possible therapies, using every available method to move new treatments to patients as quickly as possible. The FDA continues to support clinical trials that are testing new treatments for COVID so that they gain valuable knowledge about their safety and effectiveness.

The startup's CEO is a former Merck executive who previously led two life sciences companies in the Philadelphia suburbs.

Westport, CT, April 24, 2020 -- In vitro studies demonstrated decrease of viral production by over 98%Upon approval, clinical trial to be conducted at Mayo Clinic under the.

Westport, CT, April 23, 2020 -- Merimepodib is shown to decrease viral production of COVID-19 coronavirus more than remdesivir at clinically meaningful drug concentrations in.

You've probably heard by now of Gilead's promising COVID-19 drug, remdesivir. But there's another experimental drug that just might capture investors' attention in the near future.